AOD-9604: The Fat-Loss Peptide That Didn't Pan Out

AOD-9604 has an unusually instructive history for a peptide still sold online. It was not a back-alley compound. It was a genuine pharmaceutical candidate, developed by Metabolic Pharmaceuticals and tested in real clinical trials for obesity. And then it failed to deliver, which is precisely the part the marketing leaves out.

Where it came from

AOD-9604 is a fragment of human growth hormone — specifically the C-terminus, described in the published literature as Tyr-hGH177-191, with an added tyrosine for stability. The thinking was elegant: growth hormone has fat-mobilizing effects, but it also raises blood sugar and disrupts metabolism in ways you would not want in an obesity drug. Isolate just the lipolytic fragment, the reasoning went, and you might get the fat loss without the baggage.

That part held up on safety. A 2013 pooled analysis by Stier and colleagues in the Journal of Endocrinology and Metabolism, covering roughly 900 participants across six trials, found AOD9604 had a safety and tolerability profile indistinguishable from placebo, with no effect on IGF-1 levels and no negative effect on carbohydrate metabolism — unlike full-length growth hormone. So far, so clean.

Healthcare worker in a laboratory holding test tubes during pharmaceutical research

What the human trials showed

Safety, however, is not efficacy. An early 12-week Phase IIa study reported encouraging weight loss in a low-dose group versus placebo. But the result that decides a drug’s fate is the larger confirmatory trial — and that is where AOD-9604 came apart.

In its pivotal 24-week Phase IIb trial of more than 500 obese adults, AOD-9604 failed to produce statistically significant weight loss versus placebo. Metabolic Pharmaceuticals discontinued development as an obesity drug in 2007.

That is why it never advanced to approval. It is not that the compound was dangerous and pulled — its safety record was, if anything, its strongest feature. It is closer to the more common scientific outcome: a promising mechanism that simply failed to do the job in people.

Scientist examining samples under a microscope during a clinical research study

Why this matters for what you see online

AOD-9604 is still marketed, often emphasizing its growth-hormone pedigree and animal-study fat-burning effects while omitting the human trial outcome.

Assorted supplement and vitamin capsules representing products sold without the oversight of an approved drug

The selling point is mechanism, not measured weight loss.
The decisive human efficacy data is disappointing.
Products sold today are not held to the testing standards the original drug candidate was.

For how this sits against the rest of the category, see peptides for fat loss.

The trial record in one table

Study	Size	Outcome
Phase IIa, 12 weeks	Smaller cohort	Encouraging weight loss in a low-dose group
Phase IIb, 24 weeks	500+ obese adults	No statistically significant weight loss vs placebo
Pooled safety analysis (Stier et al., 2013)	Multiple trials	Well tolerated

The middle row is the one that decided the compound’s future, and it is the row least likely to appear in a product description.

A caveat on “proved safe”

The trial safety record is real, and it is also narrower than it sounds. Reviewing AOD-9604 for compounding, the FDA states it “has identified no, or only limited, safety-related information” and therefore “lacks sufficient information to know whether the drug would cause harm when administered to humans” — adding that it “has also identified serious adverse events that may be associated with AOD-9604, though causality is not clear.”

Both things are true at once. A pharmaceutical-grade compound tested under trial conditions accumulated a good tolerability record; a compounded or gray-market product bought online is a different object, and the regulator’s view of that object is not reassuring.

Frequently asked questions

Does AOD-9604 work for fat loss?

Not on the decisive evidence. In its pivotal 24-week Phase IIb trial of more than 500 obese adults, AOD-9604 failed to produce statistically significant weight loss against placebo. That is why it never advanced to approval.

If it failed, why is it still sold?

Because the marketing leans on mechanism and its growth-hormone pedigree rather than on the trial result. The story “a fragment of human growth hormone that targets fat metabolism” survives the failure of the study that tested it.

Is AOD-9604 safe?

Its trial record was good on tolerability. The FDA’s separate review of it as a compounding substance is more guarded: limited safety information, insufficient basis to know whether it would cause harm, and serious adverse events that may be associated with it, causality unclear.

Is AOD-9604 FDA approved?

No. It was developed as a drug candidate and did not reach approval, and it is now flagged among bulk substances that may present significant safety risks in compounding.

Is AOD-9604 banned in sport?

It has been treated as prohibited under the growth-hormone-fragment provisions of anti-doping rules. Anyone subject to testing should check the current WADA Prohibited List rather than rely on a general statement.

The takeaway

AOD-9604 is not mysterious or suppressed. It was tested as an obesity drug in hundreds of people, proved safe, and largely did not work for weight loss — which is why you do not hear physicians prescribing it for that purpose. When a peptide’s pitch leans heavily on its origins and safety while staying quiet about efficacy, that silence is usually the most important data point.

Sources

Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans (Journal of Endocrinology and Metabolism, 2013)